160970-86-5 Usage
Uses
Used in Pharmaceutical Industry:
(R)-(-)-1-(3-Acetoxypropyl)-5-[2-[2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethylamino]propyl]indoline-7-carboxamide is used as an impurity in the synthesis of O-Acetyl Silodosin, which is an α1a-adrenoceptor antagonist. It plays a role in the development and quality control of Silodosin, a drug used for the treatment of benign prostatic hypertrophy.
Used in Drug Development:
(R)-(-)-1-(3-Acetoxypropyl)-5-[2-[2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethylamino]propyl]indoline-7-carboxamide may also be used in drug development as a potential therapeutic agent or as a lead compound for further optimization. Its specific interactions with biological targets could make it a candidate for treating various diseases or conditions, depending on its pharmacological properties and efficacy.
Check Digit Verification of cas no
The CAS Registry Mumber 160970-86-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,6,0,9,7 and 0 respectively; the second part has 2 digits, 8 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 160970-86:
(8*1)+(7*6)+(6*0)+(5*9)+(4*7)+(3*0)+(2*8)+(1*6)=145
145 % 10 = 5
So 160970-86-5 is a valid CAS Registry Number.
160970-86-5Relevant academic research and scientific papers
1,5,7-trisubstituted indoline compounds and salts thereof
-
, (2008/06/13)
Indoline compounds represented by the formula: STR1 wherein R represents a saturated or unsaturated aliphatic acyl group which may have one or more halogen atoms, a hydroxy group, a lower alkoxy group, a carboxy group, a lower alkoxycarbonyl group, a cycloalkyl group or an aryl group as substituents; a hydroxyalkyl group; an aliphatic acyloxyalkyl group; a lower alkyl group having a lower alkoxy group, a carboxy group, a lower alkoxycarbonyl group, an aryl substituted lower alkoxycarbonyl group, a carbamoyl group, a mono- or dialkyl substituted carbamoyl group or a cyano group as substituents; an aromatic acyl group which may have one or more halogen atoms as substituents; a furoyl group or a pyridylcarbonyl group; R1 represents a lower alkyl group which may have one or more halogen atoms or an aryl group as substituents; and pharmaceutically acceptable salts thereof, exhibit a selective suppressive action on urethral contractions, and thus are useful as therapeutic agents for the treatment of dysuria with less hypotension including postural hypotension.
